Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and sold 7,500 shares for approximately $190,000 on April 29, 2026, reducing his direct holdings by 41.66%. The sale was part of a Rule 10b5-1 trading plan and should not be interpreted as a signal about his conviction in the company. Maze reported positive phase 2 trial data for MZE829 in March and maintains $360 million in cash with runway into 2028.

05/07/2026, 8:12 AM • The Motley Fool

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics (MAZE) priced an underwritten offering of 5.54 million shares at $23.50 per share, plus pre-funded warrants, raising $150 million in gross proceeds. The company plans to use net proceeds to advance development of MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, with expected cash runway into 2029. The offering includes participation from major investors including Farallon Capital, T. Rowe Price, and Janus Henderson.

04/22/2026, 12:09 AM • GlobeNewswire

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics' Chief Medical Officer Harold Bernstein sold all 15,000 of his direct shares (~$442,000) on April 1, 2026, as part of a pre-established Rule 10b5-1 trading plan adopted in September 2025. While the complete disposition of direct holdings might appear concerning, the sale was executed through a planned trading arrangement designed to avoid insider trading accusations. Bernstein retains over 237,000 stock options. The sale occurred during a market decline following the stock's 52-week high of $53.65 in March. Maze Therapeutics remains a high-risk clinical-stage biotech with no revenue and a net loss of $131.1 million, dependent on FDA approval of its lead kidney drug MZE829.

04/04/2026, 7:36 PM • The Motley Fool

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears

Harold Bernstein, President and Chief Medical Officer of Maze Therapeutics, exercised and sold 30,000 shares on March 10, 2026, generating ~$1.51 million. The sale was part of a pre-arranged Rule 10b5-1 trading plan. Despite eliminating his direct equity ownership, Bernstein retains 267,407 stock options. The transaction occurs less than a month before the company's Q4 2025 earnings report scheduled for April 6.

03/21/2026, 10:17 PM • The Motley Fool

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge

Harold Bernstein, Chief Medical Officer of Maze Therapeutics, exercised and sold 15,000 shares for approximately $690,300 on February 2, 2026, fully divesting his direct ownership. The sale was part of a pre-arranged 10b5-1 trading plan and should not concern investors. Despite the insider sale, Bernstein retains nearly 300,000 stock options, and the company continues to be viewed as a strong buy by Wall Street analysts with strong clinical trial progress.

02/16/2026, 1:35 AM • The Motley Fool

Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock

Amy Bachrodt, SVP of Finance at Maze Therapeutics, sold 5,000 shares for approximately $227,612 on January 22, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurs after the company's stock surged 157% in 2025, its first year as a public company. While the strong performance is notable, analysts suggest investors should watch for potential short-term drawdowns, though the company's long-term prospects remain promising as it advances clinical trials for kidney and metabolic disease treatments.

02/01/2026, 4:13 AM • The Motley Fool

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Maze Therapeutics announced that CEO Jason Coloma will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The clinical-stage biopharmaceutical company is developing small molecule precision medicines for kidney and metabolic diseases, with lead programs MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (advancing to Phase 2 for PKU and chronic kidney disease).

01/05/2026, 7:00 AM • GlobeNewswire

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Maze Therapeutics appointed Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy. Hoppenot brings over three decades of biotech leadership experience and previously served as CEO of Incyte Corporation.

10/06/2025, 7:00 AM • GlobeNewswire

Biotech Breakouts: 3 Stocks With Massive Upside Potential

The article highlights three biotech stocks with significant potential growth: Viking Therapeutics, ImmunityBio, and Maze Therapeutics, each showing promising clinical trial results and analyst optimism despite current market volatility.

09/18/2025, 7:05 AM • Investing

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Maze Therapeutics announced the appointment of Misbah Tahir as CFO, bringing over 20 years of financial experience in the biopharmaceutical industry. Tahir will support the company's growth strategy and upcoming clinical milestones for precision medicine treatments targeting kidney and metabolic diseases.

09/02/2025, 7:00 AM • GlobeNewswire